This newsletter presents you the following key sessions:
1. PODCAST with dr. Thierry André about the final overall survival results of the Keynote-177 trial
2. Significantly improved progression-free survival with cabozantinib in patients with previously treated
radioiodine-refractory differentiated thyroid cancer
3. Marizomib fails to demonstrate clinical benefit in patients with newly diagnosed glioblastoma
4. Meaningful objective response rate with trastuzumab deruxtecan in HER2-associated advanced
colorectal cancer: Updated results from the phase II DESTINY-CRC01 study
5. RELATIVITY-047; evaluating the anti-LAG-3 antibody relatlimab plus nivolumab in patients with
previously untreated advanced melanoma
